Age-related macular degeneration (AMD) is the commonest cause of severe visual loss and blindness in Europe and affects almost 30 percent of the older population. The chronic disease progresses slowly from early AMD to intermediate AMD (iAMD) and ultimately late-stage AMD with severe and frequently irreversible visual loss of central vision.
The objectives of macustar are to characterize the functional deficit in iAMD and to develop and validate functional, structural and patient reported outcome measures for iAMD. In addition, risk factors for progression from iAMD to late AMD will be investigated.
Dr. Hannah Dunbar is working as an optometrist at Moorfields Eye Hospital in London and is researching the effect of eye disease on a person’s everyday life at the UCL Institute of Ophthalmology. In macustar she studies the functional tests in intermediate AMD. Learn more about what motivates Hannah and what we are doing in macustar and follow this link.
This video is adapted for people with low vision.
macustar is supported by the Innovative Medicines Initiative (IMI) with a financial contribution of 8.025 million Euros, which will be complemented by an in-kind and in-cash contribution of 8.067 million Euros provided by EFPIA partners and ZEISS Meditec AG.
The macustar Project, Fact sheet of the macustar project on the website of the Innovative Medicines Initiative (IMI), Information about AMD
and other related links…
